Anzeige
Mehr »
Login
Freitag, 25.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Warum diese Minenaktie Ihre beste Absicherung gegen wirtschaftliches Chaos sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QK3 | ISIN: US87165D2080 | Ticker-Symbol:
NASDAQ
25.10.24
22:00 Uhr
8,400 US-Dollar
-0,600
-6,67 %
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
SYNERGY CHC CORP Chart 1 Jahr
5-Tage-Chart
SYNERGY CHC CORP 5-Tage-Chart
GlobeNewswire (Europe)
36 Leser
Artikel bewerten:
(0)

Synergy CHC Corp. Announces Closing of Initial Public Offering

WESTBROOK, Maine, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy"), a provider of consumer health care, beauty, and lifestyle products, announced today the completion of its initial public offering of 1,150,000 shares of its common stock at $9.00 per share. The shares of common stock began trading on the Nasdaq Global Market on October 23, 2024 under the ticker symbol "SNYR." In addition, Synergy granted the underwriters a 30-day option to purchase up to an additional 172,500 shares of common stock at the public offering price less underwriting discounts and commissions.

The net proceeds received by Synergy from the offering (after deducting underwriting discounts and commission and estimated offering expenses) were approximately $8.4 million. Synergy intends to use the net proceeds of this offering to repay a portion of outstanding amounts under certain related party promissory notes and for general corporate purposes, including working capital.

Roth Capital Partners acted as the sole manager for the offering.

The offering was made only by means of a prospectus contained in Synergy's registration statement on Form S-1, as amended. Copies of the prospectus relating to the offering may be obtained from Roth Capital Partners, 888 San Clemente Drive, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at rothecm@roth.com.

A registration statement on Form S-1 relating to this offering was declared effective by the Securities and Exchange Commission (the "SEC") on October 22, 2024 and an additional registration statement on Form S-1 relating to the offering was filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, which became automatically effective upon filing. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health care, beauty, and lifestyle products. Synergy's current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking statements." These forward-looking statements, including statements regarding Synergy's use of proceeds from the offering, represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the prospectus filed with the SEC in connection with Synergy's public offering. The risk factors and other factors noted in Synergy's prospectus could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations Contact:

Gateway Group
Cody Slach and Alex Thompson
949.574.3860
SNYR@gateway-grp.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.